ReviewInternational journal of molecular sciences2021

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.

Edouard Dantoing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.